Many thanks Icro Meattini. For the paper see: thelancet.com/journals/lanon…

#DEBBRAH cohort 5 of TDXd tx for pts with leptomeningeal disease 7 pts: 4 HER-2 low, 3 HER-2 + OS = 13.3 months mPFS =8.9 months CBR 74% IMO....very encouraging data in a small sample! #SABCS23 SABCS #bcsm

Presented today at #SABCS23 and published in JAMA results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers OncoAlert SABCS AACR Università di Genova Ospedale San Martino Genova #bcsm Link here: jamanetwork.com/journals/jama/…

#SABCS23 | Matteo Lambertini, MD PhD: supporting data for TD-Xd intracranial activity in both stable and active brain metastasis and in the leptomeningeal disease. #breastcancer #trastuzumabderuxtecan Ospedale San Martino Genova Armando Orlandi Giampaolo Bianchini

#SABCS23 | Icro Meattini: good news from San Antonio about the integration of #radiationtherapy with TD-Xd in #breastcancer patients with brain metastasis. Matteo Lambertini, MD PhD

First preliminary encouraging data from our institution on the combination of intracranial and extracranial RT ☢️ with T-DXd‼️No significant association with G3 or higher acute toxicity. Room for future evaluation in larger cohorts. #SABCS23 #BreastCancer Oncoinfo OncoAlert

PERSIAN trial will offer the unique opportunity to evaluate SBRT in a selected cohort of oligometastatic metachronous patients. It reached 30% of planned accrual! Vanessa,Pietro Garlatti,ALESSIO BRUNI acrobat.adobe.com/id/urn:aaid:sc…

Confirmed importance of ovarian suppression (especially plus AI) for premenopausal HR+/HER2+ patients, irrespectively of adjuvant trastuzumab administration in the HERA trial #ESMO2024 #ESMO24 #breastcancer

Registry of stage 1 TNBC (>1100 pts) pCR: 57.3% pCR associated w/ better OS (HR 0.29) OncoAlert #bcsm #ESMO24

Magnitude of benefit in iDFS with adjuvant ribociclib plus NSAI seems to be higher for younger patients. #ESMO2024 #ESMO24 #breastcancer

Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer

#esmo2024 Meghna Trivedi presents results from I-SPY2.2 Dato-DXd plus Durva. This personalized approach to therapy allows optimal efficacy with reduced toxicity in 50% with most achieving pCR without anthracyclines. Imp model for trials ⁦OncoAlert⁩

Neoadjuvant pembrolizumab or placebo plus chemotherapy for triple negative #breastcancer - Overall Survival results from the KEYNOTE-522 phase 3 trial #ESMO24 NEJM ESMO - Eur. Oncology #OncoAlert OncoAlert

Multicentre retrospective study comparing safety outcomes of BC patients treated with T-DXd with or without concomitant RT (379P). No impact on acute toxicity development and T-DXd discontinuation ‼️Icro Meattini Ivica Ratosa CarlottaB Viola Salvestrini Andrea Morandi #ESMO2024 #ESMO24

Very Happy to present early results from STARR trial (NCT05455736) at ASTRO! #ASTRO24 ,Vanessa ,Pietro Garlatti

Great EORTC Breast Cancer Group Autumn Meeting in Paris Institut Curie ! 2 days of insightful presentations and productive discussions on current and future activities of the group! Michail ignatiadis Etienne Brain Christos Sotiriou EORTC OncoAlert #breastcancer #bcsm

EMBER-3: imlunestrant alone or imlunestrant plus abemaciclib vs fulvestrant in patients previously treated with ET (prior CDK4/6i in 60% of patients). Imlunestrant effective as monotherapy in ESR1m patients, in combination with abema benefit showed for all patients #SABCS24

Association between risk reducing surgeries and survival in young BRCA carriers with #BreastCancer Accumulating crucial evidence presented by amazing Prof Matteo Lambertini #SABCS24 Matteo Lambertini, MD PhD OncoAlert #OncoAlert

Esclusive RT vs ET for older women >70y with pT1N0 luminal A tumors. Less impact on HRQoL with RT at the first interim analysis. Wonderful presentation by Icro Meattini, very well done! Proud to be part of this project. See the concomitant publication on Lancet Oncology! #SABCS

Welcome back ESMO - Eur. Oncology #ESTRO25 Stronger, together 💪 👉 Chairing with G Curigliano MD PhD ESMO President Elect - the ESTRO-ESMO Symposium on Integration of Novel Systemic Therapies into #Radiotherapy (3 May 2025) bit.ly/3UNMfqo ESTRO OncoAlert #OncoAlert #medonc #radonc